Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890567 | 0.93 | ABCB1 (0.49) | LMNATDP1ADRB2ADRB1KDM4E | |
| SCHEMBL4887668 | 0.92 | ADRB2 (0.43) | LMNATDP1ADRB2ADRB1KDM4E | |
| SCHEMBL8265350 | 0.91 | ADRB2 (0.45) | LMNATDP1ADRB2ADRB1KDM4E | |
| SCHEMBL5631067 | 0.90 | MAPT (0.44) | LMNAADRB2ADRB1CYP3A4MAPT | |
| SCHEMBL5630730 | 0.90 | MAPT (0.44) | LMNAADRB2ADRB1CYP3A4MAPT | |
| SCHEMBL4883182 | 0.90 | KMT2A (0.40) | LMNAADRB2ADRB1KDM4EGLA | |
| SCHEMBL4884792 | 0.88 | MAPT (0.39) | LMNATDP1ADRB2ADRB1CNR1 | |
| SCHEMBL4881191 | 0.87 | ADRB1 (0.49) | LMNATDP1ADRB2ADRB1ADRA1A | |
| SCHEMBL5630187 | 0.86 | MAPT (0.50) | LMNAADRB2ADRB1MAPTKMT2A | |
| SCHEMBL5655472 | 0.86 | MAPT (0.50) | LMNAADRB2ADRB1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | claimed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | LMNA 1122/4885TDP1 2162/4885ADRB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.